Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Gln-1062
1. Gln-1062
2. 224169-27-1
3. Galantamine Benzoate
4. Xoi2q0zf7g
5. 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, Benzoate (ester), (4as,6r,8as)-
6. Benzgalantamine
7. Unii-xoi2q0zf7g
8. Benzgalantamine [inn]
9. Schembl16885442
10. [(1s,12s,14r)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-yl] Benzoate
11. Gln 1062
12. Cs-6749
13. Hy-101710
| Molecular Weight | 391.5 g/mol |
|---|---|
| Molecular Formula | C24H25NO4 |
| XLogP3 | 4.1 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 4 |
| Exact Mass | 391.17835828 g/mol |
| Monoisotopic Mass | 391.17835828 g/mol |
| Topological Polar Surface Area | 48 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 645 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC API
GALANTAMINE BENZOATE GLUCONATE
NDC Package Code : 65129-2455
Start Marketing Date : 2021-02-24
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
The Company intends to use the proceeds towards the commercialization and launch of Zunveyl (benzgalantamine) for the treatment of mild-to-moderate Alzheimer’s Disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Brand Name: Zunveyl
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Titan Partners Group
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 12, 2024
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Titan Partners Group
Deal Size : $50.0 million
Deal Type : Public Offering
Alpha Cognition Prices $50M Upsized Public Offering and Nasdaq Listing
Details : The Company intends to use the proceeds towards the commercialization and launch of Zunveyl (benzgalantamine) for the treatment of mild-to-moderate Alzheimer’s Disease.
Brand Name : Zunveyl
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 12, 2024
Details:
The proceeds from the financing will be utilized to continue commercialization work for the Company’s recently approved Zunveyl (benzgalantamine), indicated for the treatment of Alzheimer's disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Brand Name: Zunveyl
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: The Benchmark Company, LLC
Deal Size: $4.5 million Upfront Cash: Undisclosed
Deal Type: Financing September 24, 2024
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : The Benchmark Company, LLC
Deal Size : $4.5 million
Deal Type : Financing
Alpha Cognition Completes $4.5M Convertible Note and Bridge Financing
Details : The proceeds from the financing will be utilized to continue commercialization work for the Company’s recently approved Zunveyl (benzgalantamine), indicated for the treatment of Alzheimer's disease.
Brand Name : Zunveyl
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 24, 2024
Details:
ZUNVEYL, a prodrug of AD treatment galantamine and an acetylcholinesterase inhibitor (AChEI), is postulated to exert its therapeutic effect by preventing the breakdown of acetylcholine.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Brand Name: Zunveyl
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2024
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer's Disease
Details : ZUNVEYL, a prodrug of AD treatment galantamine and an acetylcholinesterase inhibitor (AChEI), is postulated to exert its therapeutic effect by preventing the breakdown of acetylcholine.
Brand Name : Zunveyl
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 29, 2024
Details:
The company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Brand Name: ALPHA-1062
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Undisclosed
Deal Size: $6.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 22, 2023
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $6.5 million
Deal Type : Public Offering
Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering
Details : The company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Brand Name : ALPHA-1062
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 22, 2023
Details:
ALPHA-1062 (benzgalantamine), AChE inhibitor delayed-release oral tablet formulation. Currently being evaluated in the Phase III clinical trial studies for the treatment of mild-to-moderate Alzheimer’s Disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Brand Name: ALPHA-1062
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ALPHA-1062 (benzgalantamine), AChE inhibitor delayed-release oral tablet formulation. Currently being evaluated in the Phase III clinical trial studies for the treatment of mild-to-moderate Alzheimer’s Disease.
Brand Name : ALPHA-1062
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 07, 2023
Details:
The company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Brand Name: ALPHA-1062
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Undisclosed
Deal Size: $6.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 04, 2023
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $6.5 million
Deal Type : Private Placement
Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering
Details : The company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Brand Name : ALPHA-1062
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 04, 2023
Details:
The company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Brand Name: ALPHA-1062
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Spartan Capital Securities
Deal Size: $6.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 08, 2023
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Spartan Capital Securities
Deal Size : $6.5 million
Deal Type : Private Placement
Alpha Cognition Announces Third Closing of Private Placement and Continuation of the Offering
Details : The company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Brand Name : ALPHA-1062
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 08, 2023
Details:
The Company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Brand Name: ALPHA-1062
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Undisclosed
Deal Size: $97.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 16, 2023
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $97.8 million
Deal Type : Private Placement
Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering
Details : The Company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Brand Name : ALPHA-1062
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 16, 2023
Details:
ALPHA-1062, a proprietary, patented, delayed release oral tablet formulation in development for the treatment of mild-to-moderate Alzheimer’s Disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Brand Name: ALPHA-1062
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ALPHA-1062, a proprietary, patented, delayed release oral tablet formulation in development for the treatment of mild-to-moderate Alzheimer’s Disease.
Brand Name : ALPHA-1062
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 27, 2023
Details:
The Company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Lead Product(s): Galantamine Benzoate
Therapeutic Area: Neurology Brand Name: ALPHA-1062
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Undisclosed
Deal Size: $1.3 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 31, 2023
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $1.3 million
Deal Type : Private Placement
Details : The Company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.
Brand Name : ALPHA-1062
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 31, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
STOCK RECAP #PipelineProspector
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
